InnoCan Pharma

Cannabinoid-integrated Pharmaceutical Products

Health Tech & Life Sciences
Public on CSE on Sep, 2019
Public on OTCQB on Aug, 2021

Company Overview

Snapshot

Founded in October 2017 by Ron Mayron, Iris Bincovich, Nir Avram, and Yoram Drucker, InnoCan Pharma operates with 11–50 employees. The company has raised a total of $23.67M across 13 funding rounds from 4 investors. In September 2019, InnoCan Pharma completed its Initial Public Offering on the CSE.

Business overview

InnoCan Pharma is a pharmaceutical technology company specializing in cannabinoid-integrated pharmaceutical products and consumer wellness solutions. Its Pharmaceuticals segment focuses on developing innovative drug delivery platforms, including the LPT CBD-loaded liposome platform for prolonged CBD release in epilepsy and pain management, and the CLX CBD-loaded exosomes platform targeting the central nervous system for regeneration and inflammation. The Consumer Wellness segment develops and markets self-care products, with a joint venture, BI Sky Global Ltd., focused on online sales. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, with a focus on Drug Delivery and Medical Cannabis.

Strategic signal

In September 2024, InnoCan Pharma received a positive response from the FDA following a successful Pre-IND meeting regarding its Liposomal CBD, indicating progress in advancing its drug development pipeline. This regulatory validation signals a significant step forward for the company's pharmaceutical segment and its potential to bring cannabinoid-based therapies to market, which could attract further investor interest and strategic partnerships in the biopharmaceutical space.

Company Intelligence Q&A

What was a key recent regulatory milestone for InnoCan Pharma?
In September 2024, InnoCan Pharma received a positive response from the FDA following a successful Pre-IND meeting concerning its Liposomal CBD, indicating progress in its drug development efforts.
When did InnoCan Pharma complete its Initial Public Offering?
In September 2019, InnoCan Pharma completed its Initial Public Offering on the Canadian Securities Exchange (CSE).
What recent patent allowance did InnoCan Pharma receive?
In October 2025, the patent for InnoCan Pharma's Liposomal CBD Injection Technology (LPT-CBD) was allowed in Japan.
What recent scientific presentation did InnoCan Pharma make?
In September 2025, InnoCan Pharma presented a poster on its liposomal synthetic CBD technology at the PAINWeek Conference, generating interest in its research.
What recent partnership did InnoCan Pharma announce?
In September 2025, InnoCan Pharma partnered with a sanctuary for injured animals to provide its LPT-CBD injection, aiming to offer remedy and hope.

External links